Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2018-04-25

Clinical Trial Update: A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting [Phase 3]

View source ↗

Summary

The document notes the withdrawal of a Phase 3 single-arm trial evaluating home administration of Lebrikizumab for asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Asthma | Phase 3 | Status: WITHDRAWN